<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02277626</url>
  </required_header>
  <id_info>
    <org_study_id>24248</org_study_id>
    <nct_id>NCT02277626</nct_id>
  </id_info>
  <brief_title>Electro Flo 5000 and Vest Therapy</brief_title>
  <acronym>EF/Vest</acronym>
  <official_title>Comparison of the Airway Clearance Efficacy of Electro Flo 5000 and Vest Therapy in</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is the goal of the proposed study to compare the efficacy, as assessed primarily by sputum
      weight, of these two different devices (the Electroflo 500 and VEST therapy) for airway
      clearance (AC) in CF patients with mild to moderate lung disease, who have stable lung health
      and perform AC at home as part of their routine therapeutic regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wet Sputum Weight</measure>
    <time_frame>End of study visit per intervention</time_frame>
    <description>Sputum was collected in pre-measured cups in a blinded fashion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary Function Measured as a Percent Predicted BEFORE Therapy With Either ElectroFlo 5000 / VEST.</measure>
    <time_frame>End of study visit per intervention</time_frame>
    <description>Comparison of pulmonary function by doing spirometry testing on study patients during their Day 1 &amp; Day 2 therapy sessions. Will also compare the results based on the therapies they receive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary Function Measured as a Percent Predicted AFTER Therapy With Either ElectroFlo 5000 / Vest.</measure>
    <time_frame>End of study visit per intervention</time_frame>
    <description>Comparison of pulmonary function by doing spirometry testing on study patients during their Day 1 &amp; Day 2 therapy sessions. Will also compare the results based on the therapies they receive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comfort Level After Receiving Therapy With Either ElectroFlo 5000 / Vest</measure>
    <time_frame>End of study visit per intervention</time_frame>
    <description>Comfort assessed on a scale of 1-10 by patients after therapy after each visit (1 being most comfortable, 10 being most un-comfortable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dry Sputum Weight</measure>
    <time_frame>End of study visit per intervention</time_frame>
    <description>Sputum was collected in pre-measured cups in a blinded fashion, dessicated and measured dry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Randomized Crossover to ElectroFlo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: ElectroFlo 5000, then VEST Patients are randomized to a sequence of ElectroFlo 5000 on one visit and during the second visit, they cross-over to the Vest system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Crossover to Vest</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: VEST, then ElectroFlo 5000 Patients are randomized to a sequence of Vest system on one visit and during the second visit, they cross-over to the ElectroFlo 5000.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electro Flo 5000</intervention_name>
    <description>Airway clearance device</description>
    <arm_group_label>Randomized Crossover to ElectroFlo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Incourage Vest System</intervention_name>
    <description>Airway Clearance Device</description>
    <arm_group_label>Randomized Crossover to Vest</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of CF established by standard criteria (sweat chloride &gt; 60 mmol/L and/or
             two alleles affected by gene mutations know to be associated with CF).

          2. Age older than 12 years.

          3. Known to consistently produce sputum.

          4. Currently on a home therapeutic regimen that includes some form of AC performed at
             least 2 times daily.

          5. FVC and FEV1 &gt; 40%-predicted, and with stable lung function (no greater than a 10%
             variation in lung function parameters over the preceding 3 months).

        Exclusion Criteria:

          1. Hospitalization for CF pulmonary complications in the 2 months preceding enrollment.

          2. Hemoptysis &gt; 60 cc in a single episode in the 4 weeks preceding enrollment.

          3. Chronic chest pain.

          4. Participation in another interventional clinical trial in the previous 30 days. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2014</study_first_submitted>
  <study_first_submitted_qc>October 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2014</study_first_posted>
  <results_first_submitted>August 13, 2015</results_first_submitted>
  <results_first_submitted_qc>December 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 12, 2016</results_first_posted>
  <last_update_submitted>December 7, 2015</last_update_submitted>
  <last_update_submitted_qc>December 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Carlos Milla</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vest First Then ElectroFlo</title>
          <description>Experimental: VEST, then ElectroFlo 5000 15 Patients were recruited from the Cystic Fibrosis Program at Stanford. All 15 patients were randomized to a sequence of Vest at one visit and during the second visit, they crossed-over to the ElectroFlo 5000.
EnCourage Vest System: Airway Clearance Device</description>
        </group>
        <group group_id="P2">
          <title>ElectroFlo First Then Vest</title>
          <description>Experimental: ElectroFlo 5000, then VEST 15 Patients were recruited from the Cystic Fibrosis Program at Stanford. All 15 patients were randomized to a sequence of ElectroFlo 5000 at one visit and during the second visit, they crossed-over to the Vest.
Electro Flo 5000: Airway clearance device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Number of Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.33" lower_limit="12.78" upper_limit="53.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Wet Sputum Weight</title>
        <description>Sputum was collected in pre-measured cups in a blinded fashion</description>
        <time_frame>End of study visit per intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vest</title>
            <description>VEST Arm
Incourage Vest System: Airway Clearance Device</description>
          </group>
          <group group_id="O2">
            <title>Elecflo Arm</title>
            <description>Elecflo Arm
Electro Flo 5000: Airway clearance device</description>
          </group>
        </group_list>
        <measure>
          <title>Wet Sputum Weight</title>
          <description>Sputum was collected in pre-measured cups in a blinded fashion</description>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="1.1" upper_limit="6.5"/>
                    <measurement group_id="O2" value="4.6" lower_limit="0.8" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dry Sputum Weight</title>
        <description>Sputum was collected in pre-measured cups in a blinded fashion, dessicated and measured dry</description>
        <time_frame>End of study visit per intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vest Arm</title>
            <description>Vest Arm
Incourage Vest System: Airway Clearance Device</description>
          </group>
          <group group_id="O2">
            <title>ElectroFlo Arm</title>
            <description>ElectroFlo Arm
Electro Flo 5000: Airway clearance device</description>
          </group>
        </group_list>
        <measure>
          <title>Dry Sputum Weight</title>
          <description>Sputum was collected in pre-measured cups in a blinded fashion, dessicated and measured dry</description>
          <units>gram</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0" upper_limit="0.31"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0" upper_limit="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pulmonary Function Measured as a Percent Predicted BEFORE Therapy With Either ElectroFlo 5000 / VEST.</title>
        <description>Comparison of pulmonary function by doing spirometry testing on study patients during their Day 1 &amp; Day 2 therapy sessions. Will also compare the results based on the therapies they receive.</description>
        <time_frame>End of study visit per intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ElectroFlo Arm</title>
            <description>ElectroFlo Arm
Electro Flo 5000: Airway clearance device</description>
          </group>
          <group group_id="O2">
            <title>Vest Arm</title>
            <description>Vest arm
Incourage Vest System: Airway Clearance Device</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function Measured as a Percent Predicted BEFORE Therapy With Either ElectroFlo 5000 / VEST.</title>
          <description>Comparison of pulmonary function by doing spirometry testing on study patients during their Day 1 &amp; Day 2 therapy sessions. Will also compare the results based on the therapies they receive.</description>
          <units>percentage of predicted value</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.43" lower_limit="55.81" upper_limit="89.05"/>
                    <measurement group_id="O2" value="72.93" lower_limit="54.89" upper_limit="90.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pulmonary Function Measured as a Percent Predicted AFTER Therapy With Either ElectroFlo 5000 / Vest.</title>
        <description>Comparison of pulmonary function by doing spirometry testing on study patients during their Day 1 &amp; Day 2 therapy sessions. Will also compare the results based on the therapies they receive.</description>
        <time_frame>End of study visit per intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vest Arm</title>
            <description>Vest Arm
EnCourage Vest System: Airway Clearance Device</description>
          </group>
          <group group_id="O2">
            <title>ElectroFlo Arm</title>
            <description>ElectroFlo Arm
Electro Flo 5000: Airway clearance device</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function Measured as a Percent Predicted AFTER Therapy With Either ElectroFlo 5000 / Vest.</title>
          <description>Comparison of pulmonary function by doing spirometry testing on study patients during their Day 1 &amp; Day 2 therapy sessions. Will also compare the results based on the therapies they receive.</description>
          <units>percentage of predicted value</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8" lower_limit="57.36" upper_limit="94.24"/>
                    <measurement group_id="O2" value="75.73" lower_limit="58.56" upper_limit="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comfort Level After Receiving Therapy With Either ElectroFlo 5000 / Vest</title>
        <description>Comfort assessed on a scale of 1-10 by patients after therapy after each visit (1 being most comfortable, 10 being most un-comfortable)</description>
        <time_frame>End of study visit per intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vest Arm</title>
            <description>Vest Arm
EnCourage Vest System: Airway Clearance Device</description>
          </group>
          <group group_id="O2">
            <title>ElectroFlo Arm</title>
            <description>ElectroFlo Arm
Electro Flo 5000: Airway clearance device</description>
          </group>
        </group_list>
        <measure>
          <title>Comfort Level After Receiving Therapy With Either ElectroFlo 5000 / Vest</title>
          <description>Comfort assessed on a scale of 1-10 by patients after therapy after each visit (1 being most comfortable, 10 being most un-comfortable)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" lower_limit="0.84" upper_limit="7.02"/>
                    <measurement group_id="O2" value="2.67" lower_limit="0.49" upper_limit="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vest Arm</title>
          <description>Vest arm
Incourage Vest System: Airway Clearance Device</description>
        </group>
        <group group_id="E2">
          <title>ElectroFlo Arm</title>
          <description>ElectroFlo Arm
Electro Flo 5000: Airway clearance device</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carlos Milla, MD</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-5193</phone>
      <email>cmilla@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

